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p resendy, the eosinophil is recognized as a proinflamma- 
tory granulocyte imphcated in protection against para- 
sitic infection and hkely plays a major rote in allergic dis- 
eases, such as bronchial asthma,  allergic rhinitis,  and atopic 
dermatitis  (1).  The eosinophil is a rich source of cytotoxic 
proteins,  hpid  mediators,  oxygen  metabohtes,  and  cyto- 
kines: all with the potential to induce pathophysiology (2). 
Numerous studies have shown striking eosinophil infiltra- 
tion  into  tissues  in  disease.  For  example,  even  in  mild 
asthma  (3) eosinophil and lymphocyte infiltration  in respi- 
ratory epithelium is a consistent finding.  Correlations exist 
between the number of infiltrating  eosinophils and disease 
severity in asthma  (3). Pulmonary segmental allergen chal- 
lenge in sensitive individuals causes eosinophil recruitment 
into the airways associated with release of biologically ac- 
tive granule proteins and increases in vascular permeabihty 
(4, 5). Marked eosinophil infiltration and deposition of gran- 
ule proteins are found in areas ofepithehal desquamation in 
paranasaI  sinus tissues in patients with chronic sinusitis  (6). 
Deposition of eosinophil granule proteins is also prominent 
in pruritic  and eczematous lesions of patients  with  atopic 
dermatitis  (7).  In contrast,  infiltration  of neutrophils  is not 
prominent  in chronic allergic inflammation  (8,  9). Yet, in 
spite  of numerous  studies  (10),  the  mechanisms  allowing 
selective infiltration  of eosinophils in allergic diseases  have 
been a mystery for more than two decades (11). 
Several  mechanisms  for selective eosinophil  infiltration 
in disease are known. The migration ofleukocytes through 
the endothehum involves sequential steps in which the cells 
are  initially  hghtly  tethered  to  the  endothehum  and  roll 
along its surface. Locally released mediators, some of which 
may be attached  to proteoglycans  on the  endothelial  sur- 
face, activate leukocytes leading to increased affinity and/or 
increased expression of cell surface integrins;  this permits a 
firmer bond between the leukocyte and the endothelial cell 
and results in successful adhesion and transmigration.  These 
general mechanisms of leukocyte infiltration  are apphcable 
to eosinophils  and provide opportunities  for selective mi- 
gration.  First,  eosinophils  but not neutrophils  express the 
[31  integrin  ct4131 [very late antigen  (VLA-4)],  and the [37 
integrin,  0t4137, and VLA-4 binds to the vascular cell adhe- 
sion molecule (VCAM)-I  on endothehal  cells.  This adhe- 
sion pathway may permit selective migration of eosinophils 
(12).  VCAM-1  on endothelial cells is upregulated by IL-4 
and  IL-13,  important  cytokines  in  allergic  inflammation, 
and increased expression of these cytokines may further en- 
hance eosinophil recruitment  (13).  This hypothesis is sup- 
ported by the observation that eosinophil, but not neutro- 
phil,  adhesion  and  transmigration  through  monolayers  of 
human  umbilical  vein  endothelial  cells  (HUVEC)  is  en- 
hanced  by  IL-4  (14)  and  by  findings  that  antibodies  to 
VLA-4 block eosinophil infiltration in guinea pigs (15, 16). 
However,  the  expression  of VCAM-1  in  human  allergic 
inflammation  is  relatively  modest  compared  to  the  other 
adhesion molecules, such as selectins and intercellular adhe- 
sion molecule (ICAM)-I  (17), raising doubts about the im- 
portance of this mechanism for selective eosinophil infiltra- 
tion  in  disease.  Second,  among  the  eosinophil  growth 
factors, IL-5 possesses chemokinetic and chemotactic activ- 
ities for eosinophils, but not for other leukocytes (18).  Al- 
though  IL-5 is a relatively weak chemoattractant,  it effec- 
tively  and  specifically  primes  eosinophils  for  enhanced 
chemotactic responsiveness to suboptimal concentrations of 
platelet-activating factor (PAF) and leukotriene B 4 (LTB4) 
(19). Thus, a highly effective but nonspecific mediator, such 
as  PAF  (20),  could  combine  with  a  highly  selective  but 
weakly chemotactic agent, such as IL-5, to promote the speci- 
fic eosinophil  accumulation.  Evidence for the importance 
of IL-5 in eosinophil-associated inflammation abounds. IL-5 
is the predominant  eosinophil-active cytokine in the aller- 
gen-induced  pulmonary  late-phase  allergic  reaction  (21). 
Antibodies against IL-5 prevent both eosinophil migration 
into the lungs and airway hyperreactivity in allergen-chal- 
lenged monkeys and guinea pigs  (22, 23).  Mice rendered 
IL-5 deficient by homologous gene recombination  fail  to 
develop eosinophil  infiltration  into  the  lungs,  airway hy- 
perresponsiveness,  and lung damage in a model of asthma 
(24).  In contrast, mice transgenic for human IL-5 have ex- 
tremely high  numbers  of circulating  eosinophils yet show 
no pathology nor organ localization  (25), thus pointing to 
the  critical  importance  of local  IL-5  production.  Finally, 
both IL-2 (26) and IL-16 (lymphocyte chemoattractant fac- 
tor)  (27) are exceedingly potent chemoattractants for eosino- 
phils.  However, in spite  of the  potency and specificity of 
these chemoattractants their roles in the induction of eosino- 
phil tissue infiltration remain obscure. 
An exciting development in the area of eosinophil biol- 
ogy has  been  the  identification  of chemotactic  cytokines 
termed "chemokines." The chemokines have four conserved 
cysteine residues that form characteristic disulfide bonds and 
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position of the first two conserved cysteines (28).  The C-C 
subfamily chemokines,  typified by regulated upon activa- 
tion in normal T  cells  expressed and secreted (RANTES), 
are potently chemotactic for eosinophils, as well as lympho- 
cytes, but not for neutrophils  (29).  RANTES  and mono- 
cyte chemotactic protein (MCP)-3 are among the most po- 
tent  chemokines  for  eosinophil  chemotaxis  in  vitro  (29, 
30). MCP-2 and macrophage inflammatory protein (MIP)- 
let  also  induce  eosinophil  migration  (31,  32),  but  to  a 
much lesser extent than MCP-3 or R_ANTES.  In contrast, 
MCP-1  and MIP-I[3 do not induce  eosinophil chemotaxis 
(33).  The  bioactivities  and/or  protein  levels  of MIP-lot, 
R_ANTES, and MCP-3 were increased in bronchoalveolar 
lavage (BAL)  fluids from patients with asthma (34)  consis- 
tent with a role for these molecules in disease.  In addition, 
RANTES  has been localized in  the  nasal  epithelia of pa- 
tients with nasal polyps (35),  and the expression of MCP-3 
mRNA, but not RANTES mRNA, correlated with eosin- 
ophil infiltration in allergic skin reactions (36).  Intradermal 
injection  of RANTES  in  dogs  caused  an  eosinophil-rich 
infiltration within several hours; in contrast, IL-8 injection 
caused neutrophil infiltration (37).  Another C-C subfamily 
chemokine, eotaxin, was discovered in the guinea pig (38) 
and is present during allergic airway inflammation (39).  In- 
tradermal injection of guinea pig eotaxin or LTB4 in com- 
bination  with  intravenous  injection  of IL-5  stimulated  a 
rapid and dramatic increase in the number of eosinophils in 
the  skin  (40),  whereas intradermal  and intravenous  injec- 
tions of IL-5 did not. Murine  (41) and human (42) homo- 
logues  of eotaxin  have  been  recently  identified.  Eotaxin 
induces  chemotaxis  of eosinophils,  but  not  neutrophits, 
monocytes,  or  lymphocytes in  vitro,  indicating  a  highly 
specific action of this chemokine. Furthermore, human eo- 
taxin was more effective at inducing eosinophil infiltration 
than  RANTES  when  injected  into  the  skin  of a  rhesus 
monkey (42),  and eotaxin was expressed in epithelium and 
submucosa of human nasal  polyp tissues  (42)  which  com- 
monly  show  striking  and  selective  eosinophil  infiltration 
(43).  To  add  to  this  increasing  list  of eosinophil-active 
chemokines,  Uguccioni  et al.  reported another novel hu- 
man C-C chemokine, designated MCP-4 in the May issue 
of the Journal of Experimental Medicine (44).  MCP-4  shares 
60%  amino  acid  sequence  identit7  with  MCP-3  and  eo- 
taxin and is a potent chemoattractant for eosinophils, lym- 
phocytes, and monocytes (44); with eosinophils, MCP-4 is 
as potent as eotaxin and likely more potent than MCP-3. 
Thus, the C-C chemokines, including R_ANTES, MCP-3, 
eotaxin and the newly identified MCP-4, are selective and 
effective eosinophil chemokines in vitro and in vivo. 
While identification of C-C chemokines has contributed 
greatly to our understanding  of eosinophil biology, infor- 
mation regarding receptors mediating the functions of these 
chemokines is relatively sparse.  The known  C-C  chemo- 
kine receptors are members of the  G  protein-coupled re- 
ceptor superfamily; two of these receptors, CKR-1 (45,  46) 
and CKR-2 (47),  are found on mature and immature mye- 
loid cells, B lymphocytes and monocytic cell lines. CKR-1 
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binds MIP-lot, RANTES, and MCP-3, and CKR-2 binds 
MCP-1  with  high  affinity and MCP-3  with low affinity. 
More recently, Power et al.  (48) identified a new receptor, 
called CKR-4, in a human basophil cell line, which reacts 
with MCP-1, MIP-lot, and R.ANTES. In the meantime, by 
the  characteristic  pattern  of the  desensitization  of [Ca2+]i 
signals,  Dahinden et al.  (30)  speculated on the existence of 
two  chemokine receptors on eosinophils:  (a)  a  RANTES 
receptor that binds RANTES and MCP-3; and (b) a MIP-lot 
receptor that binds MIP-lot, RANTES  and,  with low af- 
finity, MCP-3.  In the May & June issues  of the Journal of 
Experimental Medicine, two groups of investigators (49,  50) 
independently report the cloning and expression of a novel 
C-C  chemokine  receptor,  designated  CKR-3,  from  pe- 
ripheral blood eosinophils  and from an eosinophil  cDNA 
library.  The sequences of CKR-3 identified by these two 
groups are identical and show 50-60% amino acid identity 
with CKR-1 and CKR-2B. CKR-3 transfected cells bound 
eotaxin, MCP-3 and RANTES with high affinity; no bind- 
ing of MIP-lel,  MIP-t[3,  or IL-8 was observed. Eotaxin, 
RANTES, and to a lesser extent MCP-3 activated CKR-3, 
as determined by stimulation of an increased [Ca2+]i and by 
chemotaxis of clones expressing the receptor. The binding 
affinities of eotaxin, MCP-3,  and RANTES for peripheral 
blood eosinophils  (49)  and the responses of eosinophils to 
these  three  cytokines  (50)  were  similar to  the  clones  ex- 
pressing  CKR-3.  Furthemaore,  on  eosinophils  CKR-1  is 
expressed at only 1-5% of the levels of CKR-3  (49).  Im- 
portantly,  CKR-3 was expressed only by eosinophils,  and 
not by neutrophils,  monocytes,  or lymphocytes, as shown 
by Western blot analysis  (49),  flow cytometry, and North- 
ern blot analysis  (50). 
CKR-3 has features which distinguish it from other C-C 
chemokine receptors and which suggest a role in the selec- 
tive eosinophil infiltration into tissues.  First,  it is expressed 
at high levels on eosinophils, 40,000  (50)  to 400,000  (49) 
receptors per cell, compared to CKR-1 and CKR-2, which 
are expressed on monocytes and T  cells usually at <3,000 
receptors per cell (37, 51). This 10-100-fold excess of CKR-3 
over CKR-1  and CKR-2 is consistent with the high  po- 
tency  of CKR-3  ligands  as  eosinophil  chemoattractants. 
Second, although most chemokine receptors are expressed 
on a number of leukocyte types, CKR-3 is expressed only 
on  eosinophils.  This  restricted  expression  of CKR-3  on 
eosinophils may determine the highly selective recruitment 
of eosinophils  in  allergic  inflammation.  Third,  CKR-3  is 
the only eotaxin receptor identified to date.  This apparent 
high degree of fidelity contrasts to R.ANTES, which binds 
to  CKR-1  (45,  46)  and  CKR-4  (48),  and  to  MCP-3, 
which binds to CKR-1  (45,  46)  and CKR-2 (47).  There- 
fore, an interaction between eotaxin and CKR-3 could lead 
to  selective  recruitment  of eosinophils,  but  not  of other 
leukocytes. Finally, CKR-3 is likely largely responsible for 
mediating  the  effects of other  potent  eosinophil  chemo- 
kines,  including  RANTES  and  MCP-3.  CKR-3  is  ex- 
pressed at 10-100  times the level of CKR-1  (49),  a differ- 
ence that  more than  compensates for the  fourfold greater 
affinity of CKR-I for RANTES and MCP-3 compared to CKR-3. In addition, MCP-4, the potent C-C chemokine 
identified by Uguccioni et al. also fikely binds to eosinophils 
via CKR-3, as judged by the results of cross-desensitization 
of [Ca2+]i signals  (44).  Thus, the discovery of CKR-3 pro- 
vides a potential mechanism for the selective recruitment of 
eosinophils into tissues during allergic inflammation. It will be 
important to know whether disrupting this eotaxin-CKR-3 
interaction prevents eosinophil specific tissue recruitment. 
Although C-C chemokines are potent chemotactic factors, 
not all the known properties of the chemokines involve leu- 
kocyte migration.  A  fascinating spectrum of activities has 
been attributed to RANTES, including T  cell proliferation, 
IL-2  receptor  expression,  and  IL-2 and  IL-5 production, 
although  higher  concentrations  (1,000  nM)  of RANTES 
were  required  for these  functions  than  those  required  for 
chemotaxis (0.1 nM) (52). RANTES and MIP-lcr at 0.1 nM 
also stimulated T  cells to express matrix metaUoproteinases, 
enzymes required for cells to migrate through the basement 
membrane  barrier  (53).  Another  potentially  important 
function of RANTES and MIP-lci is reported by Kimata 
et  al.  in  the  May issue  of Journal of Experimental Medicine 
(54).  They found  that surface IgE positive (slgE +) B  cells 
and  slG4 +  B  cells  isolated  from  human  tonsil,  but  not 
slgE-  B  cells  or  slgG4-  B  cells,  express  receptors  for 
RANTES and MIP-10~. ILANTES and MIP-lo~ at 100 nM 
directly stimulated these slgE + and slgG4  + B  cells and en- 
hanced IgE and IgG4 production; production of IgG, IgG1, 
IgG2, IgG3, IgA1  or IgA2 was not affected. A  variety of 
other  C-X-C and C-C  chemokines tested in their report 
did not show any effects. These observations suggest that a 
subpopulation of B  cells  committed to IgE and IgG4 pro- 
duction  specifically  express  receptors  for  and  respond  to 
1LANTES  and  MIP-loL.  Thus,  RANTES  and  MIP-10~ 
have the capacity to modulate allergic inflammation by reg- 
ulating  immunoglobulin  production.  RANTES  also  in- 
duces eosinophil degranulation  in vitro  (55).  Further,  it is 
likely  that  many of the  previously described  "histamine- 
releasing  factors"  for  basophils  can  be  attributed  to  C-C 
chemokines, such as MCP-1, MCP-3 and to a lesser extent 
RANTES  (30).  Therefore, although  the in vivo effects of 
these  chemokines  remain  to  be  elucidated,  C-C  chemo- 
kines  may modulate  allergic  inflammation  by their  non- 
chemotactic activities, as well as by well-known chemotac- 
tic properties. 
Thus, considerable evidence indicates important roles for 
C-C  chemokines  in  allergic  inflammation  (Fig.  1).  Still, 
questions remain.  First,  are the involved C-C chemokines 
specific for allergic inflammation? For example, eotaxin in 
mice is not restricted to a TH2-type response, and eotaxin is 
also upregulated by LPS administration, a stimulus favoring 
neutrophilia rather than eosinophilia (56).  Second, are there 
species specific responses? For example, MIP-lot is a strong 
eosinophil  chemoattractant  in  mice;  yet,  the  activity  of 
+  IChemoattractantsl  (~ 
Figure  1.  Chemokines  and allergic inflammation. Selective  tissue infil- 
tration of eosinophils is one of the striking features of allergic inflamma- 
tion. Chemokines, such as eotaxin, RANTES, MCP-3, and MCP-4, 
strongly and selectively induce chemotaxis of eosinophils via a unique 
chemokine receptor, CKR-3. This action of chemokines may be critical 
for selective eosinophil recruitment. Chemokines also stimulate various 
effector functions of T cells, B cells, and basophils. See text for details. 
MIP-lc~ is limited in humans. In mice, the effects of  MIP-lo~ 
appear to be mediated through the murine CKR-3 homo- 
logne,  which  also  binds  and  signals  with  murine  eotaxin, 
rather than through  CKR-1  (57).  Therefore,  information 
derived from animal experimentation may not be directly 
applicable to humans.  Finally, it is predicted that the total 
number of chemokines, when finally known, could exceed 
100 (58), and the attractive explanation for selective eosino- 
phil tissue infiltration provided by current information may 
be complicated by new data.  For example, deletion of the 
NH2-terminal residue of MCP-1,  a chemokine not active 
on eosinophils, converted it to a potent eosinophil chemo- 
attractant (59).  It is conceivable that current knowledge of 
the known chemokines represents only a fraction of their 
activities.  Therefore,  a  key question  remains:  will  inhibi- 
tion of a single chemokine or receptor suppress eosinophil- 
associated  inflammation?  Currently,  eotaxin  and  CKR-3 
show promise as molecules playing pivotal roles in eosino- 
phil infiltration and are exceedingly attractive target(s)  for 
therapeutic  intervention  in  allergic  diseases.  Inhibition  of 
eosinophil-specific chemokines and cellular infiltration may 
also provide insight into the pathophysiologic mechanisms of 
allergic  and  other  disease conditions.  There is  compelling 
evidence  that  links  neutrophils  and  C-X-C  chemokines 
with tissue damage in inflammatory diseases  (60),  and the 
disruption of this cascade is beneficial for the host. In aller- 
gic diseases,  glucocorticoids remain the backbone of ther- 
apy;  however,  the  beneficial  effects  of these  agents  are 
counterbalanced by their side effects. The specificity of the 
newly discovered chemokines and their receptors may per- 
mit  new  therapies  for  eosinophil-associated  disease  with 
glucocorticoid-like actions,  but without  their serious  side 
effects. 
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